Industry News
Pharmaceutical Industry News
Pfizer is laying off 100 employees…
Pfizer is laying off 100 employees in Bothell, Washington, which used to host Seagen’s global headquarters.
Weeks after telegraphing a series…
Weeks after telegraphing a series of upgrades to its Mexico operations over the next five years, Bayer is rolling up its sleeves with plans to overhaul a drug ingredient facility in Veracruz.
Nusano, a privately…
Nusano, a privately held physics company that specializes in making medical radioisotopes, cut the ribbon at a much-needed manufacturing plant in Utah.
On Monday, Argenx reported that…
On Monday, Argenx reported that its chief drug Vyvgart met the mark in a phase 3 trial assessing the FcRn blocker in the subset of generalized myasthenia gravis patients who are seronegative. Overall, seronegative patients
The company touts a large U.S….
The company touts a large U.S. market opportunity for scPharmaceuticals’ Furoscix, which recently expanded into chronic kidney disease.
Less than three weeks after…
Less than three weeks after lifting a pause on the use of Valneva’s chikungunya vaccine Ixchiq, the FDA has done an about-face, banning the use of the shot in the United States.
The U.S. drug regulator has…
The U.S. drug regulator has unveiled a plan to dramatically speed up adverse event reporting.
BeOne Medicines is monetizing its…
BeOne Medicines is monetizing its stake in Amgen’s first-in-class lung cancer drug Imdelltra for up to $950 million.
America First? Not When It Comes to Your Health.
They hoped to make tomorrow’s medicines. Then came Trump.
Where U.S. Medicines Are Made and How Trump’s Tariffs Could Affect Them
President Trump’s planned pharmaceutical tariffs threaten to hit many of the most common and well-known drugs that Americans take.
On a day when Bavarian Nordic…
On a day when Bavarian Nordic reported booming sales and adjusted its 2025 guidance positively, its CEO said that a private equity buyout of the Danish company would provide the funding it needs to realize
Talks between the U.K. government…
Talks between the U.K. government and the biopharma industry have broken down over efforts to lower rebate rates under a national drug cost-containment scheme.
Despite boasting a new owner, the…
Despite boasting a new owner, the Indiana manufacturing plant that Novo Nordisk picked up as part of its parent company's Catalent buyout last year continues to catch flak from the FDA.
U.S. pharma bounced back in Q2,…
U.S. pharma bounced back in Q2, and in this episode of "The Top Line," Fierce Pharma's Eric Sagonowsky and Kevin Dunleavy break down the numbers, company highlights and the rivalries behind the rebound.
Serena Williams has a new doubles…
Serena Williams has a new doubles partner. The 23-time Grand Slam tennis champion is working with Ro, speaking out about how she used the direct-to-patient telehealth company to access GLP-1s for weight loss after having
Johnson & Johnson is spending…
Johnson & Johnson is spending part of its big U.S. investment at a Fujifilm site. Three Indian drugmakers issued U.S. drug recalls in recent weeks due to impurities. Japan's Santen Pharma licensed a VEGF/FGF bispecific
CVS Health, the parent of PBM…
CVS Health, the parent of PBM juggernaut CVS Caremark, won’t presently add Gilead’s twice-yearly pre-exposure prophylaxis drug Yeztugo to its commercial plans or Affordable Care Act formularies, a company spokesperson confirmed to Fierce Pharma.
Since 2008, the FDA has approved…
Since 2008, the FDA has approved 11 treatments for the rare genetic condition hereditary angioedema, including three in the last two months. The latest drug to join this group of medicines arrived Thursday with the
A new campaign from AbbVie…
A new campaign from AbbVie highlights the “full selves” of people with conditions treated by the company’s therapies, in a push to show the broader impact of the medicines, according to Matt Tritley, AbbVie’s vice
The therapy offers a more…
The therapy offers a more accessible option to patients with hematological malignancies (blood cancers) who don't have access to suitable donor cells for traditional stem cell transplants.